Legend Biotech vs Travere Therapeutics
Legend Biotech (LEGN), health care, and Travere Therapeutics (TVTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Travere Therapeutics is worth $4.9B on the stock market and Legend Biotech $3.1B: Travere Therapeutics is valued at 57% more. Legend Biotech's operating margin in its latest fiscal year was -13.3% and Travere Therapeutics's -12.8%. Over the past year Legend Biotech's share price has moved -45.6% and Travere Therapeutics's +38.1%.
Key facts
- Legend Biotech market value
- $3.1B
- Travere Therapeutics market value
- $4.9B
- Legend Biotech revenue
- $1BFY to 2025-12-31
- Travere Therapeutics revenue
- $490.7MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Legend Biotech | Travere Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $3.1Blower | $4.9Bhigher |
| Revenue | $1Bhigher | $490.7Mlower |
| Earnings | -$296.8Mlower | -$25.5Mhigher |
| Employees | 3,300higher | 497lower |
| Total assets | $1.7Bhigher | $605.2Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 3.0lower | 10.0higher |
| P/B | 2.5lower | 217higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -13.3%lower | -12.8%higher |
| Balance sheet | ||
| Net assets | $1Bhigher | $114.8Mlower |
| Total liabilities | $731.6Mhigher | $490.4Mlower |
| Total debt | $319.1M | — |
| Cash on hand | $901.9Mhigher | $93Mlower |
| Price change | ||
| Today | +0.75%lower | +2.82%higher |
| 1 year | -45.6%lower | +38.1%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Legend Biotech only (1)
- Zhang Lei20.8%
Travere Therapeutics only (1)
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns LEGN · Who owns TVTX
More on Legend Biotech
Further comparisons
Legend Biotech against its closest peers
Travere Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Legend Biotech or Travere Therapeutics?
By market value, Travere Therapeutics is the larger: $4.9B against $3.1B for Legend Biotech. By revenue in its latest fiscal year, Legend Biotech is the larger: $1B against $490.7M for Travere Therapeutics.
Which has the higher operating margin?
Travere Therapeutics: -12.8%, against -13.3% for Legend Biotech. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Legend Biotech and Travere Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Legend Biotech and 1 holds Travere Therapeutics.
Cite this page
Funkfolio, “Legend Biotech vs Travere Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/legn-vs-tvtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.